Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Get Thin MD vs Voxy

Get Thin MD
Graded #184

Higher grade

vs+4.600000000000001
Voxy
Graded #280

Lower grade

The verdict

Get Thin MD takes it — 66.7/100 to 62.1/100.

Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
50
50
Dose & formulationGet Thin MD +13
77
64
Clinical oversightGet Thin MD +8
90
82
Labs & monitoringVoxy +8
55
63
FulfillmentGet Thin MD +13
91
78
Contract termsEven
20
20
Get Thin MD · left barVoxy · right bar

The numbers

MetricGet Thin MDVoxy
WeighScore66.7/10062.1/100
GradeCC
Scorecard rank#184#280
Semaglutide$199/mo (compounded)$179/mo (compounded)
Tirzepatide$299/mo (compounded)$299/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Get Thin MD

Graded #184 · C

Strengths

  • 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
  • Price-lock promise — same price every dose, no hidden fees
  • Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
  • Nationwide availability with async evaluation — no in-person visit
  • Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols

Where it loses points

  • Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
  • Pharmacy partners not named — no way to verify the compounding source or batch testing
  • Claims nationwide coverage but publishes no state list — confirm at intake
  • Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
  • Wide wellness funnel may steer you toward non-weight-loss protocols
Voxy

Graded #280 · C

Strengths

  • Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
  • Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
  • One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
  • True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
  • Free assessment with no charge to see if you qualify, and no labs required to start

Where it loses points

  • No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
  • No refund policy published; the only stated commitment language is 'cancel anytime'
  • Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
  • No public list of states served; availability depends on where affiliated providers are licensed
  • The prescribing nurse practitioner is not named — 'provider details available during your consultation'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard